

# Pharmaceutical Benefits Advisory Committee

---

---

Email: [PBAC@health.gov.au](mailto:PBAC@health.gov.au)

Address all mail to:  
PBAC Secretariat  
GPO Box 9848  
Canberra ACT 2601

## DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 JANUARY 2024

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

### **Item**

### **PBAC Advice**

Hydralazine

The sponsor requested the delisting of Alphapress 25<sup>®</sup> and Alphapress 50<sup>®</sup> (hydralazine) from the Pharmaceutical Benefits Scheme (PBS).

The PBAC noted the importance of hydralazine in the management of hypertension, especially in urgent situations and in renal disease, and advised the delisting of these products may result in an unmet clinical need. The Department sought to retain these products in line with this advice, however the sponsor indicated retention was not viable due to financial reasons and wished to proceed with the delisting.

Vanessa McMahon  
Director  
PBAC Assessment Section  
Office of Health Technology Assessment  
Technology Assessment and Access Division  
12 December 2023